477 related articles for article (PubMed ID: 21730794)
1. Gene expression of vascular endothelial growth factor A, thymidylate synthase, and tissue inhibitor of metalloproteinase 3 in prediction of response to bevacizumab treatment in colorectal cancer patients.
Watanabe T; Kobunai T; Yamamoto Y; Matsuda K; Ishihara S; Nozawa K; Iinuma H; Ikeuchi H
Dis Colon Rectum; 2011 Aug; 54(8):1026-35. PubMed ID: 21730794
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic significance of a D-dimer cut-off level of >3 µg/ml in colorectal cancer patients treated with standard chemotherapy plus bevacizumab.
Mochizuki S; Yoshino T; Kojima T; Fuse N; Ikematsu H; Minashi K; Yano T; Tahara M; Kaneko K; Doi T; Koike K; Ohtsu A
Jpn J Clin Oncol; 2010 Oct; 40(10):933-7. PubMed ID: 20494948
[TBL] [Abstract][Full Text] [Related]
3. Bevacizumab in combination with chemotherapy: first-line treatment of patients with metastatic colorectal cancer.
Hochster HS
Semin Oncol; 2006 Oct; 33(5 Suppl 10):S8-14. PubMed ID: 17145525
[TBL] [Abstract][Full Text] [Related]
4. Predictive value of expression of ERCC 1 and GST-p for 5-fluorouracil/oxaliplatin chemotherapy in advanced colorectal cancer.
Noda E; Maeda K; Inoue T; Fukunaga S; Nagahara H; Shibutani M; Amano R; Nakata B; Tanaka H; Muguruma K; Yamada N; Yashiro M; Ohira M; Ishikawa T; Hirakawa K
Hepatogastroenterology; 2012; 59(113):130-3. PubMed ID: 21940361
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer.
Kim SH; Kwon HC; Oh SY; Lee DM; Lee S; Lee JH; Roh MS; Kim DC; Park KJ; Choi HJ; Kim HJ
Am J Clin Oncol; 2009 Feb; 32(1):38-43. PubMed ID: 19194123
[TBL] [Abstract][Full Text] [Related]
6. Thymidylate synthase protein expression: Association with response to neoadjuvant chemotherapy and resection for locally advanced gastric and gastroesophageal adenocarcinoma.
Alexander HR; Grem JL; Hamilton JM; Pass HI; Hong M; Fraker DL; Steinberg SM; McAtee N; Allegra BC; Johnston PG
Cancer J Sci Am; 1995; 1(1):49-54. PubMed ID: 9166454
[TBL] [Abstract][Full Text] [Related]
7. Comparative analysis of thymidylate synthase at the protein, mRNA, and DNA levels as prognostic markers in colorectal adenocarcinoma.
Ren DN; Kim IY; Koh SB; Chang SJ; Eom M; Yi SY; Seong SH; Kim MD; Bronner MP; Cho MY
J Surg Oncol; 2009 Dec; 100(7):546-52. PubMed ID: 19722231
[TBL] [Abstract][Full Text] [Related]
8. Validation of biomarkers associated with 5-fluorouracil and thymidylate synthase in colorectal cancer.
Xi Y; Formentini A; Nakajima G; Kornmann M; Ju J
Oncol Rep; 2008 Jan; 19(1):257-62. PubMed ID: 18097604
[TBL] [Abstract][Full Text] [Related]
9. Relationship between TYMS and ERCC1 mRNA expression and in vitro chemosensitivity in colorectal cancer.
Cho YB; Chung HJ; Lee WY; Choi SH; Kim HC; Yun SH; Chun HK
Anticancer Res; 2011 Nov; 31(11):3843-9. PubMed ID: 22110208
[TBL] [Abstract][Full Text] [Related]
10. Prospective validation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumab.
Loupakis F; Cremolini C; Yang D; Salvatore L; Zhang W; Wakatsuki T; Bohanes P; Schirripa M; Benhaim L; Lonardi S; Antoniotti C; Aprile G; Graziano F; Ruzzo A; Lucchesi S; Ronzoni M; De Vita F; Tonini G; Falcone A; Lenz HJ
PLoS One; 2013; 8(7):e66774. PubMed ID: 23861747
[TBL] [Abstract][Full Text] [Related]
11. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.
Ciaparrone M; Quirino M; Schinzari G; Zannoni G; Corsi DC; Vecchio FM; Cassano A; La Torre G; Barone C
Oncology; 2006; 70(5):366-77. PubMed ID: 17179731
[TBL] [Abstract][Full Text] [Related]
12. Role of CA19.9 in predicting bevacizumab efficacy for metastatic colorectal cancer patients.
Formica V; Massara MC; Portarena I; Fiaschetti V; Grenga I; Del Vecchio Blanco G; Sileri P; Tosetto L; Skoulidis F; Pallone F; Roselli M
Cancer Biomark; 2009; 5(4):167-75. PubMed ID: 19729826
[TBL] [Abstract][Full Text] [Related]
13. Gene expression profiles of epidermal growth factor receptor, vascular endothelial growth factor and hypoxia-inducible factor-1 with special reference to local responsiveness to neoadjuvant chemoradiotherapy and disease recurrence after rectal cancer surgery.
Toiyama Y; Inoue Y; Saigusa S; Okugawa Y; Yokoe T; Tanaka K; Miki C; Kusunoki M
Clin Oncol (R Coll Radiol); 2010 May; 22(4):272-80. PubMed ID: 20117921
[TBL] [Abstract][Full Text] [Related]
14. Intratumoral expression profiling of genes involved in angiogenesis in colorectal cancer patients treated with chemotherapy plus the VEGFR inhibitor PTK787/ZK 222584 (vatalanib).
Wilson PM; Yang D; Azuma M; Shi MM; Danenberg KD; Lebwohl D; Sherrod A; Ladner RD; Zhang W; Danenberg PV; Trarbach T; Folprecht G; Meinhardt G; Lenz HJ
Pharmacogenomics J; 2013 Oct; 13(5):410-6. PubMed ID: 22664478
[TBL] [Abstract][Full Text] [Related]
15. [Evaluation of bevacizumab for advanced colorectal cancer].
Naito M; Hoshino S; Noda N; Nakano M; Matsuo K; Yamauchi Y; Shinohara T; Tanaka S; Yamashita Y
Gan To Kagaku Ryoho; 2010 Jan; 37(1):83-8. PubMed ID: 20087037
[TBL] [Abstract][Full Text] [Related]
16. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer.
Kabbinavar FF; Hambleton J; Mass RD; Hurwitz HI; Bergsland E; Sarkar S
J Clin Oncol; 2005 Jun; 23(16):3706-12. PubMed ID: 15867200
[TBL] [Abstract][Full Text] [Related]
17. [Bevacizumab in combination with mFOLFOX6 or FOLFIRI for previously treated metastatic colorectal cancer].
Koyama M; Murata A; Kimura Y; Sakamoto Y; Morohashi H; Kimura N; Gasa F; Sato J; Terui K; Awatsu A; Hakamada K
Gan To Kagaku Ryoho; 2010 Jun; 37(6):1069-73. PubMed ID: 20567110
[TBL] [Abstract][Full Text] [Related]
18. Thymidylate synthase gene expression in primary colorectal cancer and metastatic sites.
Yamada H; Ichikawa W; Uetake H; Shirota Y; Nihei Z; Sugihara K; Hirayama R
Clin Colorectal Cancer; 2001 Nov; 1(3):169-73; discussion 174. PubMed ID: 12450430
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of tailored chemotherapy for advanced colorectal cancer with either 5-fluouracil and leucovorin or oxaliplatin and irinotecan based on the expression of thymidylate synthase and dihydropyrimidine dehydrogenase.
Smorenburg CH; Peters GJ; van Groeningen CJ; Noordhuis P; Smid K; van Riel AM; Dercksen W; Pinedo HM; Giaccone G
Ann Oncol; 2006 Jan; 17(1):35-42. PubMed ID: 16251201
[TBL] [Abstract][Full Text] [Related]
20. Short time infusion of bevacizumab in combination with 5FU-based chemotherapy as first-line therapy in a non-selective patient group with metastatic colorectal cancer.
Dohn LH; Jensen BV; Larsen FO
Acta Oncol; 2010 Apr; 49(3):395-6. PubMed ID: 20001495
[No Abstract] [Full Text] [Related]
[Next] [New Search]